Sign In
Buy IBRX
$7.18
-0.0500 (-0.692%)
At Close: Jun 03, 2026
IBRX and the BCG Shortage: A 2026 Catalyst Investors Are Tracking
02:40pm, Friday, 13'th Mar 2026
ImmunityBio leverages a persistent BCG shortage and expanding Anktiva use in NMIBC, with 2026 catalysts including FDA talks, global launches and new clinical milestones.
IBRX Stock: Anktiva's Approvals and What Comes Next
02:35pm, Friday, 13'th Mar 2026
ImmunityBio's Anktiva drives revenue surge and new approvals, as U.S. uptake and global launches set up a pivotal 2026.
ImmunityBio Valuation: Paying 33x Sales for Anktiva
02:35pm, Friday, 13'th Mar 2026
IBRX stock surge has pushed valuation to ~33x sales as Anktiva adoption accelerates - but the premium assumes flawless commercialization and expansion.
ImmunityBio Stock Soars 295% YTD: Time to Buy, Hold or Sell?
11:05am, Friday, 13'th Mar 2026
IBRX stock surges nearly 300% YTD as Anktiva sales jump and global approvals expand, while premium valuation and single-drug reliance raise questions.
Why Is ImmunityBio Stock Soaring On Friday?
10:44am, Friday, 13'th Mar 2026
ImmunityBio Inc. (NASDAQ: IBRX) shares are up on Friday morning as the company completed its manufacturing engineering programs for its NK cell therapy platform.
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors
07:30am, Friday, 13'th Mar 2026
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments
03:25pm, Thursday, 12'th Mar 2026
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often take a
ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug
11:03am, Monday, 09'th Mar 2026
ImmunityBio Inc. (NASDAQ: IBRX) shares are trading lower on Monday.
Following multiple meetings with the FDA, ImmunityBio submitted additional information requested by the Agency to support its supplemental BLA (sBLA) for papillary disease The FDA reviewed the additio
Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies
10:00am, Thursday, 05'th Mar 2026
ImmunityBio's recently approved cancer drug has plenty of momentum. However, valuation concerns and clinical and regulatory uncertainty make the stock risky.
ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript
11:52pm, Tuesday, 03'rd Mar 2026
ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript
ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026
07:30am, Friday, 27'th Feb 2026
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a busin
ImmunityBio Investors Rally Behind Cancer Trial Milestone
08:57am, Thursday, 26'th Feb 2026
ImmunityBio Inc. (NASDAQ: IBRX) shares are up during Thursday's premarket session as the company has completed enrollment in its pivotal randomized trial evaluating Anktiva plus Bacillus Calmette-Gué
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced completion of enrollment in its Phase 2 clinical trial evaluating ANKTIVA®
Barry Simon Sells 165,000 Shares of ImmunityBio (NASDAQ:IBRX) Stock
05:18am, Thursday, 26'th Feb 2026
ImmunityBio, Inc. (NASDAQ: IBRX - Get Free Report) Director Barry Simon sold 165,000 shares of the stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price
